Esperion Therapeutics' (ESPR) Buy Rating Reiterated at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $16.00 target price on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Esperion Therapeutics' Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.55) EPS.

Several other research firms have also recently weighed in on ESPR. The Goldman Sachs Group reduced their price objective on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Needham & Company LLC cut their target price on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Esperion Therapeutics presently has an average rating of "Hold" and an average price target of $6.25.

Esperion Therapeutics Stock Down 2.7%

ESPR stock traded down $0.03 during mid-day trading on Tuesday, reaching $1.07. 5,147,602 shares of the stock traded hands, compared to its average volume of 5,247,469. The firm has a market capitalization of $212.07 million, a PE ratio of -1.34 and a beta of 0.67. The business has a 50-day moving average of $0.96 and a two-hundred day moving average of $1.61. Esperion Therapeutics has a 52 week low of $0.69 and a 52 week high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 59.03%. The business had revenue of $65.00 million for the quarter, compared to analyst estimates of $54.97 million. On average, equities research analysts anticipate that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ESPR. Nuveen LLC acquired a new position in Esperion Therapeutics in the first quarter worth about $4,446,000. Wasatch Advisors LP boosted its stake in Esperion Therapeutics by 4.9% in the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company's stock worth $53,861,000 after purchasing an additional 1,136,245 shares in the last quarter. Nuveen Asset Management LLC boosted its stake in Esperion Therapeutics by 48.6% in the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock worth $6,862,000 after purchasing an additional 1,020,243 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Esperion Therapeutics by 45.1% during the fourth quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock worth $3,586,000 after purchasing an additional 506,428 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Esperion Therapeutics by 18.6% in the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock valued at $5,399,000 after buying an additional 385,099 shares in the last quarter. 47.39% of the stock is owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.